Logo image of BNTX

BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BNTX - US09075V1026 - ADR

95.85 USD
-1.43 (-1.47%)
Last: 12/9/2025, 4:20:02 PM
95.85 USD
0 (0%)
After Hours: 12/9/2025, 4:20:02 PM
Fundamental Rating

3

Overall BNTX gets a fundamental rating of 3 out of 10. We evaluated BNTX against 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of BNTX get a neutral evaluation. Nothing too spectacular is happening here. BNTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BNTX has reported negative net income.
In the past year BNTX has reported a negative cash flow from operations.
Of the past 5 years BNTX 4 years were profitable.
BNTX had a positive operating cash flow in 4 of the past 5 years.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

BNTX has a Return On Assets of -2.68%. This is amongst the best in the industry. BNTX outperforms 87.01% of its industry peers.
BNTX's Return On Equity of -3.09% is amongst the best of the industry. BNTX outperforms 89.45% of its industry peers.
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

Looking at the Gross Margin, with a value of 85.62%, BNTX belongs to the top of the industry, outperforming 88.14% of the companies in the same industry.
BNTX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BNTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTX has been increased compared to 1 year ago.
The number of shares outstanding for BNTX has been increased compared to 5 years ago.
The debt/assets ratio for BNTX is higher compared to a year ago.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 6.19 indicates that BNTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.19, BNTX is in the better half of the industry, outperforming 74.95% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
The Debt to Equity ratio of BNTX (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.19
ROIC/WACCN/A
WACC7.23%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 7.12 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.12, BNTX is doing good in the industry, outperforming 70.24% of the companies in the same industry.
A Quick Ratio of 7.02 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.02, BNTX is doing good in the industry, outperforming 70.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 7.02
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

BNTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.92%.
BNTX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%

3.2 Future

The Earnings Per Share is expected to grow by 14.03% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.18% on average over the next years.
EPS Next Y-16.98%
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%
EPS Next 5Y14.03%
Revenue Next Year4.3%
Revenue Next 2Y0.77%
Revenue Next 3Y1.01%
Revenue Next 5Y2.18%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTX. In the last year negative earnings were reported.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

BNTX's earnings are expected to decrease with -3.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

NASDAQ:BNTX (12/9/2025, 4:20:02 PM)

After market: 95.85 0 (0%)

95.85

-1.43 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)03-10 2026-03-10/amc
Inst Owners22.75%
Inst Owner Change-2.53%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap23.05B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts80.71
Price Target139.7 (45.75%)
Short Float %6.57%
Short Ratio7.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)1.07%
PT rev (3m)2.13%
EPS NQ rev (1m)71.47%
EPS NQ rev (3m)88.8%
EPS NY rev (1m)32.36%
EPS NY rev (3m)35.12%
Revenue NQ rev (1m)-1.79%
Revenue NQ rev (3m)-14.14%
Revenue NY rev (1m)24.33%
Revenue NY rev (3m)29.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.27
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-5.31
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS15.28
BVpS89.56
TBVpS81.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.62%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 202.92%
Cap/Sales 24.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 7.02
Altman-Z 6.19
F-Score3
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-16.98%
EPS Next 2Y-6.87%
EPS Next 3Y-3.32%
EPS Next 5Y14.03%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year4.3%
Revenue Next 2Y0.77%
Revenue Next 3Y1.01%
Revenue Next 5Y2.18%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.4%
EBIT Next 3Y12.9%
EBIT Next 5Y19.79%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A

BIONTECH SE-ADR / BNTX FAQ

Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to BNTX.


Can you provide the valuation status for BIONTECH SE-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.


How profitable is BIONTECH SE-ADR (BNTX) stock?

BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.


How financially healthy is BIONTECH SE-ADR?

The financial health rating of BIONTECH SE-ADR (BNTX) is 5 / 10.


Can you provide the expected EPS growth for BNTX stock?

The Earnings per Share (EPS) of BIONTECH SE-ADR (BNTX) is expected to decline by -16.98% in the next year.